Eli Lilly and Co Update on SARS-CoV-2 Neutralizing Antibody Program - Conference Call Transcript

Jan 26, 2021 / 05:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the COVID-19 neutralizing antibody program update media and investor call. (Operator Instructions) As a reminder, this conference call is being recorded. (Operator Instructions) And I will now like to turn the conference over to our host, Kevin Hern. Please go ahead, sir.

Kevin Hern - Eli Lilly and Company - VP of IR

Good afternoon. Apologies for the delay and thank you for joining us for Eli Lilly and companies SARS-coronavirus-2 neutralizing antibody program update. I'm Kevin Hern, Vice President of Investor Relations.

Joining me on today's call are Dave Ricks, Lilly's Chairman and CEO; Dr. Dan Skovronsky, Chief Scientific Officer; and Josh Smiley, Chief Financial Officer. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3. Additional information concerning factors that could cause actual results to differ

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot